Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors within the central nervous process, conolidine modulates alternate molecular targets. A Science Improvements review identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabi... https://bookmarkgenius.com/story20720504/new-step-by-step-map-for-conolidin-to-replace-traditional-painkillers